Chemotherapy drugs that target a common mutation in colorectal cancer rapidly lose efficacy in patients, leading to relapse. According to a new preclinical study by Weill Cornell Medicine and MD Anderson Cancer Center investigators, colorectal tumors often find multiple ways to survive treatment, including additional genetic mutations and activation of cellular pathways typically associated with inflammation and regeneration. Targeting this tumor-specific inflammatory process could enhance the efficacy of some anticancer therapies and prevent drug resistance.
Continue Reading this article here
